Combined Surgical/Interventional-Radiological Cytoreduction in a Patient with Disseminated Highly Differentiated Neuroendocrine Ileal Tumor

A combined approach to cytoreduction in a patient with a neuroendocrine tumor G1 the ileum with multiple bilobar metastases G2 in the liver, originally considered as a candidate only for drug therapy, has been demonstrated. The first stage was laparoscopic resection of the ileocecal segment of the intestine, followed by interventional radiological intervention — a two-stage selective transarterial oil chemoembolization of the liver with bleomycin. As a result, 90 % cytoreduction, suppression of clinical manifestations, normalization of chromogranin A and serotonin were achieved. The patient continues to be observed without signs of progression for more than 4 years from the moment of diagnosis. It is shown that multidisciplinary treatment of patient with timely inclusion of interventional-radiological interventions allows achieving long-term favorable results in patients with advanced stage of disease.

1. Hallet J, Law CHL, Cukier M. Exploring the rising incidence of neuroendocrine tumors: A populationbased analysis of epidemiology, metastatic presentation, and outcomes. First published: 13 October 2014. DOI: 10.1002/cncr.29099.

2. Sacksteina PE, O’Neilbc S, Neugut I, et al. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years Author links open overlay panel. July 2008. DOI: 10.1053/j.seminoncol.2018.07.001.

3. Riihimaki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases inneuroendocrine tumors. Int J Cancer. 2016;139:2679-86. DOI: 10.1002/ijc.30400.

4. Godwin J. Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975;36:560-9. DOI: 10.1002/1097-0142(197508)36:2%3C560::AIDCNCR2820360235%3E3.0.CO;2-4.

5. McDermott E, Guduric B, Brennan M. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg. 1994;81:1007-9. DOI: 10.1002/bjs.1800810725.

6. Zappa M, Abdel-Rehim M. Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. DOI: 10.1007/s11523012-0219-8.

7. Xiang J, Zhang X, Beal E, et al. Hepatic Resection for Nonfunctional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter? Ann Surg Oncol. 2018. DOI: 10.21037/hbsn.2020.04.02.

8. Chamberlain R, Canes D, Brown K, et al. Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg. 2000;190:432-45. DOI: 10.1016/s1072-7515(00)00222-2.

9. Cloyd J, Ejaz A, Konda B, et al. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surgery and Nutrition. 2020;9(4):440=51. DOI: 10.21037/hbsn.2020.04.02.

10. Gurusamy K, Ramamoorthy R, Sharma D, et al. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev 2009;(2):CD007060. DOI: 10.1002/14651858. CD007060.pub2.

11. Pavel M, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157-76. DOI: 10.1159/000335597.

12. Maxwell J, Sherman S, O’Dorisio T, et al. Liverdirected surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016;159(1):320-35. DOI: 10.1016/j.surg.2015.05.040.

13. Morgan R, Pommier S, Pommier R. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163(1):218-25. DOI: 10.1016/j.surg.2017.05.030.

14. Gupta S, Yao J, Ahrar K. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the m.d. anderson experience. Cancer J. 2003;9(4):261-7. DOI: 10.1097/00130404-200307000-00008.

15. Mendoza-Elias N, Morrison J, Valeshabad A, et al. Decision Making for Selection of Transarterial Locoregional Therapy of Metastatic Neuroendocrine Tumors. Sem Intervent Radiol. 2017;34(02):101-8. DOI: 10.1055/s-0037-1602590.

16. Mayo SC, Pawlik TM. Surgical management of neuroendocrine tumors: treatment of localized and metastatic disease. Oncology (Williston Park) 2011;25:806, 808, 810.

17. Mayo S, de Jong M, Bloomston M, et al. Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. Ann Surg Oncol. 2011;18(13):3657-65. DOI: 10.1245/s10434-011-1832-y.

18. Osborne D, Zervos E, Strosberg J, et al. Improved Outcome With Cytoreduction Versus Embolization for Symptomatic Hepatic Metastases of Carcinoid and Neuroendocrine Tumors. Ann Surg Oncol. 2006;13(4):572-81. DOI: 10.1245/aso.2006.03.071.

19. Eriksson B, Larsson E, Skogseid B, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998 Dec 1;83(11):2293-301. PMID: 9840528.